SEC Comment Letter 0000000000-23-005274 to Oculis Holding AG (OCS, OCSAW) (CIK 0001953530) (OCS)
Oculis Holding AG (OCS, OCSAW) (CIK 0001953530)
Date: May 17, 2023 · CIK: 0001953530 · Accession: 0000000000-23-005274
AI Filing Summary & Sentiment
Letter
United States securities and exchange commission logo May 17, 2023 Sylvia Cheung Chief Financial Officer Oculis Holding AG One Gateway Center 300 Washington Street, Suite 405 Newton, MA 02458 Re:Oculis Holding AG Draft Registration Statement on Form F-1 Submitted May 10, 2023 CIK No. 0001953530 Dear Sylvia Cheung: This is to advise you that we do not intend to review your registration statement. We request that you publicly file your registration statement no later than 48 hours prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jimmy McNamara at 202-551-7349 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
United States securities and exchange commission logo
May 17, 2023
Sylvia Cheung
Chief Financial Officer
Oculis Holding AG
One Gateway Center
300 Washington Street, Suite 405
Newton, MA 02458
Re:Oculis Holding AG
Draft Registration Statement on Form F-1
Submitted May 10, 2023
CIK No. 0001953530
Dear Sylvia Cheung:
This is to advise you that we do not intend to review your registration statement.
We request that you publicly file your registration statement no later than 48 hours prior
to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you that the company and its management are responsible for the
accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or
absence of action by the staff.
Please contact Jimmy McNamara at 202-551-7349 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences